Xtl Biopharmaceuticals (XTLB) Short-term Investments (2009 - 2025)
Xtl Biopharmaceuticals (XTLB) posted quarterly Short-term Investments of $109000.0 for Q2 2025, down 89.01% year-on-year from $992000.0 in Q2 2024, and down 85.88% on a QoQ basis from $772000.0 in Q4 2024.
Xtl Biopharmaceuticals (XTLB) Short-term Investments (2009 - 2025) Analysis & Trends
Xtl Biopharmaceuticals (XTLB) has reported Short-term Investments for 17 consecutive years, with $109000.0 the latest figure, recorded in Q2 2025.
- Quarterly Short-term Investments fell 89.01% year-over-year to $109000.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $109000.0 (down 89.01% YoY) and the FY2024 annual result came in at $772000.0, up 27.6% from the prior year.
- Short-term Investments retreated to $109000.0 in Q2 2025 per XTLB's latest filing, from $772000.0 in the prior quarter.
- Over the last five years, Short-term Investments for XTLB reached as high as $3.4 million in Q2 2021 and fell as low as $109000.0 in Q2 2025.
- A 5-year average of $1.4 million and a median of $972000.0 in 2023 frame the typical range for Short-term Investments.
- Annual changes were most pronounced in 2021 — Short-term Investments surged 1664.35% — and 2025, when it sank 89.01%.
- Year by year, Short-term Investments stood at $3.2 million in 2021, then slumped by 48.48% to $1.6 million in 2022, then sank by 62.81% to $605000.0 in 2023, then climbed by 27.6% to $772000.0 in 2024, then sank by 85.88% to $109000.0 in 2025.
- According to Business Quant data, Short-term Investments over the past three periods registered $109000.0, $772000.0, and $900000.0 for Q2 2025, Q4 2024, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Xtl Biopharmaceuticals | 2.60 Bn | 2.60 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 109,000.00 |
| Dec 31, 2024 | 772,000.00 |
| Sep 30, 2024 | 900,000.00 |
| Jun 30, 2024 | 992,000.00 |
| Mar 31, 2024 | 1.27 Mn |
| Dec 31, 2023 | 605,000.00 |
| Sep 30, 2023 | 749,000.00 |
| Jun 30, 2023 | 794,000.00 |
| Mar 31, 2023 | 972,000.00 |
| Dec 31, 2022 | 1.63 Mn |
| Jun 30, 2022 | 2.81 Mn |
| Dec 31, 2021 | 3.16 Mn |
| Jun 30, 2021 | 3.38 Mn |
| Dec 31, 2020 | 2.41 Mn |
| Jun 30, 2020 | -216,000.00 |
| Dec 31, 2019 | 2.27 Mn |
| Dec 31, 2018 | 2.85 Mn |
| Sep 30, 2018 | 4.33 Mn |
| Jun 30, 2018 | 4.32 Mn |
| Mar 31, 2018 | 4.52 Mn |